Fig 1: Effect of OP-B on HCC progression and PTP1B expression in vivo. (A) HCC xenograft mice were treated with normal saline, or with 15 or 75 mg/kg OP-B for 21 days. (B) Body weight and tumor volumes were recorded every 7 days. (C) HCC tumors in different groups were removed from xenograft model and (D) weighed and the tumor/body weight was also calculated. The expression of Ki67 (E), CD31 (F) and VEGFA (G) in tumor samples of HCC xenograft mice were detected by IHC. (H) mRNA and (I) protein expression levels of PTP1B in tumor samples of HCC xenograft mice were measured by reverse transcription-quantitative PCR and western blot assays, respectively. *P<0.05, **P<0.01 and ***P<0.001 vs. control. HCC, hepatocellular carcinoma; IHC, immunohistochemistry; OP-B, ophiopogonin-B; PTP1B, protein tyrosine phosphatase 1B.
Fig 2: Effects of GQWTF on 10-week high-fat diet induced mice. Body weight A was monitored once a week, and fasting blood-glucose (FBG) (B) every 2 weeks during 10-week trial. C Dynamic changes of blood glucose during oral glucose tolerance test (OGTT), and AUC is area under the blood glucose-time curves of OGTT. D The relative protein expression of PTPN1, PPARA, PPARG and phosphorylation of INSR in liver using western blot analysis. Data are shown as means ± SEM of ten (A, B) or six (C) or three (D) independent experiments. #p < 0.05, ##p < 0.01, compared with control group; *p < 0.05, **p < 0.01, compared with model group
Fig 3: Effect of OP-B on PTP1B expression in hepatocellular carcinoma cells. (A) HHL-5 and MHCC97-H cells were exposed to different concentrations of OP-B for 24 h, then cell viability was measured by Cell Counting Kit-8 assay. MHCC97-H cells were treated with different concentrations of OP-B for 24 h, then PTP1B (B) mRNA and (C) protein expression levels were evaluated. MHCC97-H cells were either transfected with Ov-PTP1B or empty vector, then the overexpression efficiency was verified by (D) reverse transcription-quantitative PCR and (E) western blot assays. *P<0.05, **P<0.01 and ***P<0.001 vs. control. NC, negative control; OP-B, ophiopogonin-B; Ov, overexpression vector; PTP1B, protein tyrosine phosphatase 1B.
Fig 4: Effect of OP-B treatment and PTP1B overexpression on migration, invasion and angiogenesis of hepatocellular carcinoma cells. MHCC97-H cells were transfected with Ov-PTP1B or OV-NC and subsequently treated with 20 µM OP-B. (A) Cell migration was determined by wound healing assay. (B) Transwell assay was performed to observe cell invasion. (C) Tube formation assay was used to assess cell angiogenesis. (D) Protein expression levels of E-cadherin, N-cadherin, Vimentin and VEGFA were detected by western blot analysis. ***P<0.001 vs. control; ##P<0.01 and ###P<0.001 vs. OP-B + Ov-NC. NC, negative control; OP-B, ophiopogonin-B; Ov, overexpression vector; PTP1B, protein tyrosine phosphatase 1B.
Fig 5: Effect of OP-B and PTP1B overexpression on hepatocellular carcinoma cell proliferation and apoptosis. MHCC97-H cells were transfected with Ov-PTP1B or OV-NC and subsequently treated with 20 µM OP-B. (A) Cell viability was measured by Cell Counting Kit-8 assay. (B) Colony formation was performed to observe cell proliferation. (C) TUNEL staining was used to assess apoptosis. (D) Protein expression levels of apoptosis-related proteins were detected by western blotting; GAPDH was used as the loading control. ***P<0.001 vs. control; ##P<0.01 and ###P<0.001 vs. OP-B + Ov-NC. NC, negative control; OP-B, ophiopogonin-B; Ov, overexpression vector; PTP1B, protein tyrosine phosphatase 1B.
Supplier Page from Abcam for Anti-PTP1B antibody [EPR22468-6]